Kahn Brothers Group Inc De Lowers stake in Hologic (HOLX)

Hologic (HOLX) : Kahn Brothers Group Inc De reduced its stake in Hologic by 1.76% during the most recent quarter end. The investment management company now holds a total of 1,326,484 shares of Hologic which is valued at $44,768,835 after selling 23,767 shares in Hologic , the firm said in a disclosure report filed with the SEC on May 9, 2016.Hologic makes up approximately 8.60% of Kahn Brothers Group Inc De’s portfolio.

Other Hedge Funds, Including , Cutter Co Brokerage boosted its stake in HOLX in the latest quarter, The investment management firm added 1,605 additional shares and now holds a total of 11,905 shares of Hologic which is valued at $401,437. Hologic makes up approx 0.18% of Cutter Co Brokerage’s portfolio.State Board Of Administration Of Florida Retirement System reduced its stake in HOLX by selling 1,770 shares or 0.51% in the most recent quarter. The Hedge Fund company now holds 344,175 shares of HOLX which is valued at $11,605,581. Hologic makes up approx 0.04% of State Board Of Administration Of Florida Retirement System’s portfolio. Tocqueville Asset Management sold out all of its stake in HOLX during the most recent quarter. The investment firm sold 34,780 shares of HOLX which is valued $1,168,260.Texas Permanent School Fund reduced its stake in HOLX by selling 108,231 shares or 53.09% in the most recent quarter. The Hedge Fund company now holds 95,638 shares of HOLX which is valued at $3,212,480. Hologic makes up approx 0.04% of Texas Permanent School Fund’s portfolio.

Hologic closed down -0.01 points or -0.03% at $33.75 with 20,18,828 shares getting traded on Friday. Post opening the session at $33.82, the shares hit an intraday low of $33.695 and an intraday high of $34.25 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Hologic reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.46. The company had revenue of $693.30 million for the quarter, compared to analysts expectations of $687.43 million. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 EPS.

Many Wall Street Analysts have commented on Hologic. Hologic was Downgraded by Needham to ” Hold” on Apr 28, 2016.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.